Study the Relationship Between Obesity and Hepatitis C Replication

You may not be if

• BMI greater than 25 Kg/m2
• HCV-infected subjects naïve to treatment: subjects who either have never been treated for HCV infection or who previously received HCV treatment ending more than 3 months prior to enrollment for not longer than 2 weeks
• Plasma HCV RNA concentration of \>10,000 IU/mL at the screening evaluation
• Previous intolerance to Pioglitazone, Rosiglitazone, Troglitazone or corticosteroids
• Women who are pregnant or breastfeeding
• History of diabetes mellitus requiring treatment other than diet
• Decompensated liver disease or other known causes of liver disease including, but not limited to autoimmune hepatitis, Wilson's disease, hemochromatosis, primary biliary cirrhosis, schistosomiasis, sclerosing cholangitis, alcohol- or drug-induced liver disease, or alpha-one antitrypsin deficiency
• Concurrent hepatitis B virus (HBV) infection
• Known immunodeficiency disease, autoimmune disorders or active gastrointestinal disease
• Abuse of alcohol or illicit drugs within 6 months before enrollment
• Use of an investigational drug within 4 weeks before the screening visit or during the screening period.
• Use of systemic immunosuppressants
• History of poorly controlled psychiatric disease or poorly controlled pulmonary disease